QUECTEL-WIRELESS
9.4.2024 09:01:27 CEST | Business Wire | Press release
Embedded World--Quectel Wireless Solutions, a global IoT solutions provider, is delighted to announce the commercial availability of the RG255C-GL 5G RedCap Sub-6 GHz LGA module, delivering comprehensive 5G and 4G coverage across the globe. Based on Qualcomm Technologies, Inc.'s Snapdragon® X35 baseband chipset, the RG255C-GL offers exceptional wireless performance, empowering seamless low-latency 5G communication and advanced features including 5G LAN, URLLC, and network slicing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409408432/en/
Quectel broadens RedCap offering with commercial availability of RG255C-GL RedCap 5G module (Photo: Business Wire)
The RG255C-GL, conforming to 3GPP Release 17 standards, features a compact LGA form factor measuring 32.0mm x 29.0mm x 2.4mm. With impressive data rates of 223 Mbps downlink and 123 Mbps uplink, it is tailored for applications such as CPEs, MiFi, Router, Gateway, or Industrial PDA. Additionally, this module supports LTE Cat 4 and 5G Sub-6 SA mode, ensuring compatibility with Rel-15 and Rel-16 networks for seamless integration and versatile deployment.
Furthermore, the module is compatible with Quectel 4G module EG2x series modules with smaller sizes, which can meet customers’ different application demands for medium speed, large capacity, low latency, and high reliability, making it ideal for customers to design in to current device applications.
"Having the RG255C-GL 5G RedCap module commercially available offers our customers access to the benefits of 5G without the accompanying expense and power consumption," commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "This technology paves the way for diverse IoT applications requiring worldwide 4G and 5G coverage with ultra-reliable low latency communications (URLLC) and network slicing."
RG255C-GL is designed for the global market and covers nearly all the mainstream carriers worldwide. The module features Qualcomm® IZat™️ location technology, offering GPS, GLONASS, BDS, and Galileo positioning functionalities. With its integrated GNSS receiver, customers can streamline their product design while enjoying enhanced positioning capabilities with greater speed and accuracy.
A wide range of interfaces including USB 2.0, PCle 2.0, PCM, UART, SGMII and SPI alongside a large number of drivers means that this module is ideal for a wide range of RedCap applications.
Quectel prioritizes security throughout the development of its IoT modules. Starting from product architecture to firmware/software development, Quectel integrates top industry practices and standards to address potential vulnerabilities. They collaborate with third-party independent test houses to mitigate risks and implement security measures such as generating SBOMs and VEX files, as well as conducting firmware binary analysis throughout the entire software development lifecycle.
The RG255C-GL RedCap module will be available alongside a series of antennas, providing developers with the ability to purchase module and antennas at the same time, reducing cost and time to market.
Attendees to Embedded World will be able to find out more about the RG255C-GL 5G RedCap module on the Quectel stand at booth number 3-318.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240409408432/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom